Cancer Genetics (NASDAQ:CGIX) revealed net loss for the fourth quarter of $ 7.9 million or 35 cents per share, compared to loss of $ 2.8 million or 15 cents per share, in the year-ago period.
Headquartered in Rutherford, New Jersey, the company disclosed, revenue that reached $ 7.50 million, rose 4% from $ 7.20 million a year ago.
The consensus estimates from Thomson Reuters are loss of $ 0.11 per share from $ 9.19 million in revenue.
John A. (Jay) Roberts, interim CEO said, We are intently focused on enhancing our financial and competitive position through efforts to expand our Biopharma and Discovery businesses through pursuit of select new partnerships and large volume contracts in precision oncology.
Cancer Genetics is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing.